tiprankstipranks
Advertisement
Advertisement

HK:2162 Stock Latest News

Keymed Biosciences Shareholders Approve All AGM Resolutions, Renew Capital Mandates
Company AnnouncementsKeymed Biosciences Shareholders Approve All AGM Resolutions, Renew Capital Mandates
11d ago
2162
Keymed Biosciences Banks US$257 Million From Ouro Medicines Sale as Gilead-Lakefront Alliance Advances CM336
PremiumCompany Announcements
Keymed Biosciences Banks US$257 Million From Ouro Medicines Sale as Gilead-Lakefront Alliance Advances CM336
1M ago
2162
Keymed Biosciences Sets AGM to Approve Accounts, Board Changes and New Share Mandate
PremiumCompany Announcements
Keymed Biosciences Sets AGM to Approve Accounts, Board Changes and New Share Mandate
2M ago
2162
Keymed Biosciences Details Gain and Capital Plans From Ouro Medicines Stake Disposal
PremiumCompany Announcements
Keymed Biosciences Details Gain and Capital Plans From Ouro Medicines Stake Disposal
3M ago
2162
Keymed Biosciences boosts revenue on Kangyueda push while deepening R&D pipeline
PremiumCompany Announcements
Keymed Biosciences boosts revenue on Kangyueda push while deepening R&D pipeline
3M ago
2162
M&A News: Gilead Bets $2B+ on Ouro Medicines to Power Immunology Growth
PremiumMarket NewsM&A News: Gilead Bets $2B+ on Ouro Medicines to Power Immunology Growth
4M ago
GSK
GILD
Keymed Biosciences to Realize Up to US$320 Million From Ouro Medicines Exit
Premium
Company Announcements
Keymed Biosciences to Realize Up to US$320 Million From Ouro Medicines Exit
4M ago
2162
Keymed Biosciences Sets March 26 Board Meeting to Approve 2025 Results and Consider Final Dividend
Premium
Company Announcements
Keymed Biosciences Sets March 26 Board Meeting to Approve 2025 Results and Consider Final Dividend
4M ago
2162
Keymed Gains US$45 Million Milestone as AstraZeneca Starts Phase III Trial of Core Cancer Drug
PremiumCompany Announcements
Keymed Gains US$45 Million Milestone as AstraZeneca Starts Phase III Trial of Core Cancer Drug
4M ago
2162
Keymed Biosciences’ Strategic Positioning and Stapokibart’s Market Potential in Biotech Sector
PremiumRatings
Keymed Biosciences’ Strategic Positioning and Stapokibart’s Market Potential in Biotech Sector
8M ago
Keymed Biosciences Reports Strong Revenue Growth Amid Leadership Change
PremiumCompany Announcements
Keymed Biosciences Reports Strong Revenue Growth Amid Leadership Change
11M ago
2162
Keymed Biosciences Schedules Board Meeting to Review Interim Results
PremiumCompany Announcements
Keymed Biosciences Schedules Board Meeting to Review Interim Results
11M ago
2162
Keymed Biosciences Announces Successful AGM Resolutions
PremiumCompany AnnouncementsKeymed Biosciences Announces Successful AGM Resolutions
1y ago
2162
Keymed Biosciences Completes Share Placement and Subscription, Raising HK$853.77 Million
Premium
Company Announcements
Keymed Biosciences Completes Share Placement and Subscription, Raising HK$853.77 Million
1y ago
2162
Keymed Biosciences Announces Share Placement and Subscription to Raise HK$853.77 Million
Premium
Company Announcements
Keymed Biosciences Announces Share Placement and Subscription to Raise HK$853.77 Million
1y ago
2162
Keymed Biosciences Announces 2025 Annual General Meeting and Key Resolutions
PremiumCompany Announcements
Keymed Biosciences Announces 2025 Annual General Meeting and Key Resolutions
1y ago
2162
Keymed Biosciences to Review Annual Results and Dividend
PremiumCompany Announcements
Keymed Biosciences to Review Annual Results and Dividend
1y ago
2162
Keymed Biosciences Gains Approval for Stapokibart in Allergic Rhinitis Treatment
PremiumCompany Announcements
Keymed Biosciences Gains Approval for Stapokibart in Allergic Rhinitis Treatment
1y ago
2162
Keymed Biosciences Licenses CM355 to Prolium for Global Development
PremiumCompany Announcements
Keymed Biosciences Licenses CM355 to Prolium for Global Development
1y ago
2162
Keymed Biosciences Secures Licensing Deal for CM313
PremiumCompany AnnouncementsKeymed Biosciences Secures Licensing Deal for CM313
1y ago
2162
Keymed Biosciences Gains NMPA Approval for Stapokibart
Premium
Company Announcements
Keymed Biosciences Gains NMPA Approval for Stapokibart
2y ago
2162
Keymed Biosciences Relocates Hong Kong Headquarters
Premium
Company Announcements
Keymed Biosciences Relocates Hong Kong Headquarters
2y ago
2162

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >